Business
Bionano Genomics Announces Publication of Study Evaluating Optical Genome Mapping for High Throughput Characterization of Cytogenomic Heterogeneity in MDS
SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announced the publication of a study of 76 subjects by authors at The University of Texas MD Anderson Cancer Center (MD Anderson), including Dr. Guillermo Garcia-Manero, Dr. Rashmi Kanagal-Shamanna and others. The study was published in Blood, the journal of the American Society of Hematology. The study evaluated the utility of OGM as an alternative to traditional cytogenomic methods for the characterization of structural variation (SV) in myelodysplastic syndrome (MDS). MDS refers to disorders of the bone marrow in which it does not produce enough healthy blood cells. Dr. Rashmi Kanagal-Shamanna from MD Anderson commented: “The results of this study underscore the potential of optical genome mapping to become a single-platform cytogenetic tool for structural variant profiling in indications such as MDS. Structural variant profiling is as important as sequence variant or mutation profiling for proper characterization of MDS in research and patient management. Technical advances in structural variant profiling have lagged those for mutation profiling, despite the fact that large genomic aberrations have been shown to be critical for diagnosis and risk-stratification of MDS and a subset of them are therapeutic targets in clinical trials. We found that OGM provided a consolidated workflow that was simpler to perform and had a shorter turnaround time compared to the three standard methods karyotyping, CMA and FISH. Importantly, OGM was not only concordant with the traditional methods, it enabled us to see more variants in subjects at higher resolution compared to traditional workflows, which has the potential to help drive better outcomes as a result of better patient management. We are pleased with the outcome of this study and we plan to continue using OGM to help make it a standard method for structural variation profiling in the future.\"In this study, 76 subjects were selected for analysis by OGM using fresh and frozen bone marrow. Compared to karyotyping, OGM results were 100% concordant. According to this study, OGM resolution was much higher than conventional karyotyping (CK) and enabled...